Vaxxinity has selected VXX-401 to pursue as its anti-proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) vaccine candidate to treat hypercholesterolemia, and reported data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in nonhuman primates.

Classic galactosemia (CG) is an inborn error of galactose metabolism caused by a severe deficiency of galactose-1-phosphate:uridylyltransferase (GALT) enzymatic activity, which leads to accumulation of several metabolites such as galactose-1-phosphate (Gal-1-P), the substrate of GALT, and galactonate and galactitol, the oxidation and reduction products.

Researchers from Alnylam Pharmaceuticals and collaborators published data from a study that aimed to identify novel therapeutic targets for abdominal obesity by searching for genetic variants associated with lower waist-to-hip ratio.

A research team at Shanghai University and Shaanxi University of Chinese Medicine has discovered a novel lipid-lowering compound with hepatoprotective effects.